Clear Cell Renal cell carcinoma (ccRCC) is the most common form of kidney cancer. The VHL tumor suppressor is lost or mutated in the majority of ccRCC and hereditary mutations in VHL predispose ...
Alicia Morgans outlines anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk ...
(UroToday.com) The 2026 APCCC meeting featured a management of metastatic hormone-sensitive prostate cancer (mHSPC) session and a presentation by Dr. Robert Jones discussing patients who should ...
Shilpa Gupta reports 3.5-year follow-up data from EV-302. Among all patients, 44% remained alive, double the chemotherapy arm, and more than 70% of complete responders were still alive. Complete ...
Kim Chi describes KLK2-comPAS, a trial investigating pasritamig, a bispecific IgG1 antibody that binds KLK2 and CD3. Phase one and two data in heavily pretreated patients showed radiographic ...
Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the Abstract ...
Comparative Analysis of Genitourinary Toxicity Following Bladder Outlet Obstruction Procedures in Patients Before Versus After Radiotherapy for Localized Prostate Cancer: A Retrospective Cohort Study ...
Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...
Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...
(UroToday.com) The 2026 ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Sandip Prasad discussing responses to UGN-102 across EORTC recurrence score groups in ...
The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...
(UroToday.com) The 2026 ASCO annual meeting featured a radioligand innovation in prostate cancer session and a presentation by Dr. Michael Morris discussing CONVERGE-01 Part 3 assessing Ac-225 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results